There was a trend towards higher frequency of disease progression in target and non-target lesions in BRAF-MT patients and patients with right-sided primary tumor (BRAF-MT vs. BRAF-WT: 25.0% vs. 3.7%, right-sided vs. left-sided tumor: 18.8% vs. 8.6%). This evidence concerns the gene BRAF and neoplasm.